PDS Biotechnology reported steady Q2 2026 revenue but a wider operating loss as expenses rose. Higher R&D spending to advance its oncology pipeline hurt profita

BWB News TV • 2026-08-13 13:01 UTC • By Billy Odell Tucker-Robinson

PDS Biotechnology reported steady Q2 2026 revenue but a wider operating loss as expenses rose. Higher R&D spending to advance its oncology pipeline hurt profitability while the company pursued clinical milestones.

Share this article

𝕏 X / Twitter Facebook LinkedIn WhatsApp

📚 More from Billy’s World

📰 Banking With Billy News All breaking financial news & market analysis 📚 Banking With Billy Books Deep-dive books on every financial story 💬 Join the Community discord.gg/VHxwmR5j4Y 🎥 Banking With Billy on YouTube Live streams & market commentary

Banking With Billy News Network — bankingwithbilly.com
Discord: discord.gg/VHxwmR5j4Y • YouTube: @BankingWithBilly